Blue Horseshoe Stocks: RXMD Recap

Nxt-ID, Inc. NXTD

We most recently mentioned NXTD a couple of weeks ago on February 12th, following a long period of consolidation off of the massive run we observed back in December. The stock seemed to be settling down at a bottom, and indeed, it reached its low of 2.00 the very next day.

After a bit of sideways trading NXTD has awakened in a big way on the heels of a key development coming over the newswires (see snippet below). Already in the premarket, it has risen by 100% since our alert, hitting 4.00 in early trading.

In addition to the stock itself, we’re also going to place a couple of contracts in the NXTD options chain in watch, the NXTD 03/16 $2.50 & $5 Calls.

Discover Financial Services and FitPay, Inc., a wholly owned subsidiary of NXT-ID, Inc., today announced a network services agreement to allow devices that are integrated with the FitPay Payment Platform[TM] to provision tokenized payment credentials through Discover® Digital Exchange (DDX). The agreement enables Discover cardholders, along with alliance partner cards, to easily make contactless payment transactions at retail locations with wearable or Internet of Things (IoT) devices that include payment capabilities powered by FitPay[TM] (>>View Full PR)

Progressive Care, Inc. RXMD

We initially flagged RXMD in Thursday’s premarket report after noticing the amount of momentum that had been building up in the stock recently. It managed to finish out the week sustaining that momentum and continuing to head into blue skies, setting a new 52-week high with each uptick.

From Thursday morning’s low of .0663, the stock attained a high of .0979 which workes out to a two day swing of 48% and stand as the highest PPS recorded since 2013.

Fresh Options Idea:
Target Corp. TGT Weekly $75-76.50 Calls

Extended Watchlist:

Incoming search terms:

  • MIT1
  • VMKX

Blue Horseshoe Stocks: TEUM Update & More

Pareteum Corp. TEUM

The last time we mentioned TEUM was December 8th, shortly after which time the stock was trading for as little as .661. At the time the company had no involvement in the trendy cryptocurrency space.

Flash forward to this week, and an announcement that the company is adding blockchain capability for cryptocurrency support on its global cloud billing platform has the stock soaring to new highs.

TEUM hit 3.15 yesterday, which marks an increase of 377% in less than three weeks’ time. Volume for the day was on the order of roughly five times the monthly average.

Bitcoin itself has been making a nice rebound after the pullback which followed its big run to nearly $20K, and there is no reason to suspect that the push toward blockchain related technologies, both cryptocurrency and otherwise, is just a passing fad.

INSYS Therapeutics, Inc. INSY - Options Recap

We made our interest in the INSY 01/19 $8 & $9 Calls known yesterday morning, and it barely took any time at all for our ideas to come to fruition.

As we were mentioning yesterday, the company recently initiated Phase II trials of its synthetic Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy, and the FDA granted Fast Track status to the ‘drug’ for the treatment of a rare genetic disorder (Prader-Willi).

This news allowed for some very nice moves in our designated contracts. The $8 Calls ran from .35-1.00 for a gain of 186%, while the $9′s traded up from .20-.55, trending up 175% on the day.

Ampio Pharmaceuticals, Inc. AMPE

We also want to swing back to remind our readers of last week’s alert on AMPE. We tagged this play seven days ago (four trading days), and saw it trading for as little as 2.57. As of yesterday’s high of 3.55, the stock had thus far risen by 38%

The stock’s peak PPS represented a new annual high, so we’ll be interested to see how the stock performs in blue skies.

Extended Watchlist:

Blue Horseshoe Stocks: New Highs for HMNY, MNKD

Helios and Matheson Analytics, Inc. HMNY

It was just yesterday morning that we were remarking on the continuously bullish tendencies of HMNY over the past few weeks since we began tracking it on September 20th.

To that point, we had seen a huge run from a low of 5.47 to 23.49, and then yesterday’s session brought another solid performance, and yet another new high. HMNY traded in a daily range from 22.75 to 28.70. That works out to a an intraday rise of 26% and an updated total on our overall observed move since 10/20 amounting to 425%

MannKind Corp. MNKD

Yesterday we were talking about some options calls we made on Friday for MNKD, the 10/20 $5.50 & $6.00 Calls, which have made some good moves, but we neglected to mention our success on the stock side itself.

A quick view of the MNKD Tag in our newsletter archive at shows that we’ve been consistently mentioning the stock over the past several months, and four times already since the beginning of October. Our observed low on the stock alone came in at 1.85, and yesterday’s new high for MNKD represented an overall increase of 276%

Moving back to the options side of things, those $5.50 Calls traded up from .71-1.60 (+129%) intraday, and from Friday’s low of .10, a total of 1500%  The $6.00′s saw a daily range .47-1.30 (+177%), and the overall move we’ve witnessed since Friday comes in at a whopping 2500%


Fresh Options Idea:

Delta Air Lines. Inc. DAL- Not only did Delta post a Q3 earnings beat in the premarket despite taking a hit due to the recent hurricanes, but the chart is also currently headed for a Golden Cross. With that in mind, we’re going to signal the DAL Weekly $52.50-54 Calls.

Extended Watchlist:

Blue Horseshoe Stocks: KMX Recap & More

CarMax, Inc. KMX 

First up this morning, we’re going to start off the fresh trading week by reviewing the performance of the CarMax options we signaled in Friday’s premarket report on the heels of the company’s Q2 earnings beat.

We’re constantly pounding the table on post-earning options trading, simply because we are so very often successful in our selections. Volatility is a swing trader’s best friend, and few things create it more quickly and effectively than a solid beat on earnings.

So we signaled our interest in tracking the KMX Weekly $69.50-71.50 Calls and it worked like a charm:

$69.50 Calls - Range: 1.21-4.96 – Max Gain: 310%
$70 Calls – Range: 1.10-4.40 – Max Gain: 300%
$70.50 Calls – Range: .55-3.78 – Max Gain: 587%
$71 Calls – Range: .35-3.50 – Max Gain: 900%
$71.50 Calls – Range: .30-2.41 – Max Gain: 703%

Helios and Matheson Analytics, Inc. HMNY

We just updated our readers on our coverage of HMNY last Wednesday, when we pointed out that we slated the stock for tracking on August 15th and observed a subsequent low of 2.42. By midweek the stock had already made a considerable move up, but Friday’s session brought another big pop to new highs.

HMNY traded in a daily range from 5.67 to 7.95 gaining 40%, a very respectable intraday move in and of itself. The new high marked an overall move of 229% from our observed low.

Volume was much higher than average all last week, and the stock maintain roughly half of its daily advance into a fairly strong close, so we’ll need to keep monitoring HMNY for the continued establishment of higher highs and higher lows.

Extended Watchlist:

Blue Horseshoe Stocks: IDXG Recap & More

Interpace Diagnostics Group, Inc. IDXG

We last talked about IDXG on the 16th of last month. (Please excuse us for being currently unable to provide the link to that report like we normally would, as our primary servers are located in Houston, and our service provider is still recovering in the wake of Hurricane Harvey.) Subsequent to that mention, we observed a low of .72 in IDXG, and the run we’ve seen has been pretty impressive.

Yesterday the stock hit 1.73, which represents a 140% increase, and the stock closed with strength just below its high of day, so we’ll be interested to see if there will be further gains in store. The key for IDXG will be to maintain above the NASDAQ minimum bid requirement of a dollar per share on any pullbacks.

Insmed, Inc. INSM – Options Update

We highlighted our interest in a set of options for INSM in yesterday’s report to try to take advantage of the flux in activity caused by the company’s positive Phase III results on its rare lung disease treatment study.

We saw the beginnings of what could be a good idea that we’ll want to continue tracking in the INSM 09/15 $27-30 Calls. The $27′s we’re the only ones that were pushed into the money, and they did manage an intraday run from a low of .95 to 1.60 for a 68% swing on the day. We’ll continue to keep an eye on these contracts if INSM can manage to record higher lows over the next few sessions.

Extended Watchlist: